Eagle Pharmaceuticals, Inc.

EGRX

US2697961082

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.16 ^USD	-1.89%		-9.76%	-20.46%

Apr. 22	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Eagle Pharmaceuticals, Inc. Announces Delay in Third Quarter 2023 Results

November 09, 2023 at 07:58 am EST

Eagle Pharmaceuticals, Inc. announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for November 9, 2023. The company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward.

Latest news about Eagle Pharmaceuticals, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 22	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Sector Update: Health Care	Apr. 15	MT
Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise	Apr. 15	MT
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	Mar. 11	MT
Sector Update: Health Care	Mar. 11	MT
Eagle Pharmaceuticals CFO Resigns; Shares Fall	Mar. 11	MT
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
Eagle Pharmaceuticals, Inc. Announces CFO Changes	Mar. 08	CI
Eagle Pharmaceuticals, Inc. Announces Board and Committee Changes	Mar. 08	CI
Eagle Pharmaceuticals, Inc. Enters into Second Amendment to Third Amended and Restated Credit Agreement	Mar. 01	CI
Eagle Pharmaceuticals Idles 36% Workforce -- Shares Down	Feb. 29	MT
Wells Fargo Taps JPMorgan Alum for Vice Chairman	Feb. 27	DJ
Eagle Pharmaceuticals, Inc. Enters into Limited Waiver and First Amendment to Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A	Jan. 16	CI
Eagle Pharmaceuticals, Inc.(NasdaqGM:EGRX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 29	MT
Top Midday Decliners	Nov. 29	MT
Eagle Pharmaceuticals Receives Non-Compliance Notice From Nasdaq After Delay in Filing Quarterly Report	Nov. 29	MT
Eagle Pharmaceuticals, Inc. Announces Resignation of Scott Tarriff as Chief Executive Officer	Nov. 29	CI
Eagle Pharmaceuticals, Inc. Announces Management Change	Nov. 29	CI
Health Care Drops as Obesity Craze Cools -- Health Care Roundup	Nov. 09	DJ

Chart Eagle Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Companyâs subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
EAGLE PHARMACEUTICALS, INC.	-20.46%	54.03M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals